The development of a roadmap for Health Technology Assessment implementation in Moldova.

Q2 Pharmacology, Toxicology and Pharmaceutics
F1000Research Pub Date : 2024-10-21 eCollection Date: 2024-01-01 DOI:10.12688/f1000research.146025.2
Gavin Surgey, Ghenadie Curocichin, Maria Garabajiu, Tanja Novakovic, Adrian Pana, Wija Oortwijn
{"title":"The development of a roadmap for Health Technology Assessment implementation in Moldova.","authors":"Gavin Surgey, Ghenadie Curocichin, Maria Garabajiu, Tanja Novakovic, Adrian Pana, Wija Oortwijn","doi":"10.12688/f1000research.146025.2","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Moldova strives for universal health coverage (UHC) and considers health technology assessment (HTA) an important policy instrument to inform the choice of services that should be covered to progressively realize UHC. It plays a key role in determining which technologies are coved, considering various dimensions often including cost-effectiveness, budget impact, and feasibility. This paper reports on work undertaken to develop a roadmap for HTA implementation, using evidence-informed deliberative processes (EDPs) as the guiding framework.</p><p><strong>Methods: </strong>Between 2020 and 2022, we undertook several activities that informed the roadmap. We conducted a needs assessment and an assessment of European HTA best practices using a combination of desk research, interviews and surveys. We then conducted a document review of six selected HTA systems, complimented by expert interviews from three neighbouring countries.</p><p><strong>Results: </strong>The roadmap provided a suggested HTA process, which included instructions on how to execute the different steps of the EDP framework to enhance the legitimacy of HTA-informed decision-making. The roadmap encompasses several aspects such as how to organize stakeholder involvement, how to identify and operationalize decision criteria, and how to make the decision process transparent. Guidance was given to the country on establishing a legal framework for HTA; a communication strategy; strengthening capacity and leveraging HTA expertise. The country was also given tailored advice on the positioning of the HTA-agency, first as an entity within the Ministry of Health or the National Agency of Public Health but with the long-term vision for it to be independent of any state institution.</p><p><strong>Conclusions: </strong>Despite several challenges, including a partial disruption because of the Covid-19 pandemic, the development of the roadmap for HTA implementation was completed and agreed upon by the Ministry of Health in Moldova. This work has helped motivate and support the country in HTA institutionalization.</p>","PeriodicalId":12260,"journal":{"name":"F1000Research","volume":"13 ","pages":"518"},"PeriodicalIF":0.0000,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11502998/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"F1000Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.12688/f1000research.146025.2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Moldova strives for universal health coverage (UHC) and considers health technology assessment (HTA) an important policy instrument to inform the choice of services that should be covered to progressively realize UHC. It plays a key role in determining which technologies are coved, considering various dimensions often including cost-effectiveness, budget impact, and feasibility. This paper reports on work undertaken to develop a roadmap for HTA implementation, using evidence-informed deliberative processes (EDPs) as the guiding framework.

Methods: Between 2020 and 2022, we undertook several activities that informed the roadmap. We conducted a needs assessment and an assessment of European HTA best practices using a combination of desk research, interviews and surveys. We then conducted a document review of six selected HTA systems, complimented by expert interviews from three neighbouring countries.

Results: The roadmap provided a suggested HTA process, which included instructions on how to execute the different steps of the EDP framework to enhance the legitimacy of HTA-informed decision-making. The roadmap encompasses several aspects such as how to organize stakeholder involvement, how to identify and operationalize decision criteria, and how to make the decision process transparent. Guidance was given to the country on establishing a legal framework for HTA; a communication strategy; strengthening capacity and leveraging HTA expertise. The country was also given tailored advice on the positioning of the HTA-agency, first as an entity within the Ministry of Health or the National Agency of Public Health but with the long-term vision for it to be independent of any state institution.

Conclusions: Despite several challenges, including a partial disruption because of the Covid-19 pandemic, the development of the roadmap for HTA implementation was completed and agreed upon by the Ministry of Health in Moldova. This work has helped motivate and support the country in HTA institutionalization.

制定摩尔多瓦卫生技术评估实施路线图。
背景:摩尔多瓦努力实现全民医保(UHC),并认为卫生技术评估(HTA)是一项重要的政策工具,可为选择应覆盖的服务提供信息,以逐步实现全民医保。它在确定哪些技术应被纳入覆盖范围方面发挥着关键作用,通常要考虑到包括成本效益、预算影响和可行性在内的各个方面。本文以循证审议过程(EDP)为指导框架,报告了为制定 HTA 实施路线图而开展的工作:在 2020 年至 2022 年期间,我们开展了多项活动,为路线图提供信息。我们结合案头研究、访谈和调查,开展了需求评估和欧洲 HTA 最佳实践评估。然后,我们对六个选定的 HTA 系统进行了文件审查,并对三个邻国的专家进行了访谈:结果:路线图提供了一个建议的 HTA 流程,其中包括如何执行 EDP 框架不同步骤的说明,以提高 HTA 知情决策的合法性。路线图包括几个方面,如如何组织利益相关者参与、如何确定和实施决策标准以及如何使决策过程透明。在建立 HTA 法律框架、沟通战略、加强能力和利用 HTA 专业知识方面,为该国提供了指导。此外,还就 HTA 机构的定位向该国提供了有针对性的建议,该机构首先是作为卫生部或国家公共卫生机构内的一个实体,但长期愿景是独立于任何国家机构:尽管面临着一些挑战,包括因 Covid-19 大流行而造成的部分中断,但 HTA 实施路线图的制定工作已经完成,并得到了摩尔多瓦卫生部的同意。这项工作有助于激励和支持该国将 HTA 制度化。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
F1000Research
F1000Research Pharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (all)
CiteScore
5.00
自引率
0.00%
发文量
1646
审稿时长
1 weeks
期刊介绍: F1000Research publishes articles and other research outputs reporting basic scientific, scholarly, translational and clinical research across the physical and life sciences, engineering, medicine, social sciences and humanities. F1000Research is a scholarly publication platform set up for the scientific, scholarly and medical research community; each article has at least one author who is a qualified researcher, scholar or clinician actively working in their speciality and who has made a key contribution to the article. Articles must be original (not duplications). All research is suitable irrespective of the perceived level of interest or novelty; we welcome confirmatory and negative results, as well as null studies. F1000Research publishes different type of research, including clinical trials, systematic reviews, software tools, method articles, and many others. Reviews and Opinion articles providing a balanced and comprehensive overview of the latest discoveries in a particular field, or presenting a personal perspective on recent developments, are also welcome. See the full list of article types we accept for more information.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信